看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。8 _. { e) H) u; k" b
) V+ c# S7 k3 G, I3 Z4 ^) ?
, P4 g7 n5 `+ T( i% E) r$ t1 L i, I [
Currently available feasibility data for possible combination strategies.
+ X7 j3 E" ~6 R& D. h————————————————————————————————% ]/ v, E7 h+ S( D7 {2 p
Combination Feasibility according to preliminary data : @* j4 A( M6 t5 g3 Z9 v
——————————————————————————————————; Z7 N: G$ N) }- F8 U
Bevacizumab + sorafenib Yes, reduced dose 9 K, F2 P* @) i7 C o
Bevacizumab + sunitinib† No
" [# [$ ?- u* x9 }Bevacizumab + temsirolimus Yes
( |# `- E" t9 Z8 x m% ABevacizumab + everolimus Yes 0 y; P" E9 g8 o( V5 ]+ o3 `2 i
Sorafenib + sunitinib ? ( ~9 [5 I7 T9 a! e( i
Sorafenib + temsirolimus Yes, reduced dose 7 P$ d+ a P! b0 A; J% n' q
Sorafenib + everolimus Yes, reduced dose . b* e1 U1 C- K1 g
Sunitinib + temsirolimus† No
6 d* Q0 i% S, Y7 w3 w2 j- PSunitinib + everolimus ?
o1 [7 i [" {; f G. }9 X( \, FTemsirolimus + everolimus ?
; l: O, u6 V1 {/ q9 @9 g————————————————————
. n3 |! p- |6 U) }& D†Led to US FDA warning.3 @( Y5 k4 h( n6 n7 T" b j j$ o
?: As yet unattempted combination.) h! z- F( m$ Y& C2 n6 @
|